Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks

Fed-funds futures now suggest a 71.5% probability of a double rate cut ( 50 basis points) at the Federal Open Market Committee’s September meeting.

This marks a significant increase from the 22% probability prior to the release of the jobs report.

A likely fall in interest rates promises cheaper money and easier borrowing, both of which would benefit the biotech sector.

Morgan Stanley stock analysts are running with this outlook, and advising investors to buy two biotech stocks in particular.

Viking Therapeutics is a clinical-stage biopharmaceutical researcher dedicated to developing treatments for metabolic and endocrine disorders.

The pipeline features three drug candidates targeting obesity, non-alcoholic steatohepatitis (NASH), and X-linked adrenoleukodystrophy (X-ALD) Viking is optimistic about VK2809 , its candidate for NASH , and VK0214 , an orally available thyroid hormone receptor beta agonist, as a potential treatment for X-ALD.

The shares are currently trading for $ 53.05 and the stock has a 112% upside for the coming year .